Sign in

Trial result ·

Neoadjuvant PD-L1/TGF-β blockade can rapidly disrupt the tumor stroma in head and neck cancer patients.

Written based on 1 research study on PubMed, searched on 5 Nov 2026.

What was studied

This was a small early study in head and neck squamous cell cancer. 6 people got bintrafusp alfa before the main treatment. The drug blocks the proteins PD-L1 and TGF-β. Tumor samples were taken before treatment and 3 weeks later. The team looked at the tissue around the tumor.

What they found

After treatment, cells that support the tumor, called CAFs, fell in number. The tissue around the tumor had less collagen. More CD8+ T cells, a kind of immune cell, entered tumors. These tumors had kept immune cells out before. A second group of 6 people showed the same changes. The pattern pointed to loss of these support cells, not a change in their type.

What it means for patients

The authors said blocking TGF-β can disrupt the tissue around a tumor fast. They said more trials and new biomarkers are needed to pick patients who could benefit.

Why it is not certain yet

Only 6 people were in each group. The final clinical group was too small to judge the effect of the treatment. The study looked at tissue changes. The abstract does not report how patients did.

Source

Neoadjuvant PD-L1/TGF-β blockade can rapidly disrupt the tumor stroma in head and neck cancer patients.

PubMed · PMID 42969228

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Head and neck cancer publications